Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer

BACKGROUND: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14–16 nM is required for a lower recurrence rate. The aim of this study was to investigate the feasibility of reaching a...

Descripción completa

Detalles Bibliográficos
Autores principales: Braal, C. Louwrens, Jager, Agnes, Hoop, Esther Oomen-de, Westenberg, Justin D., Lommen, Koen M. W. T., de Bruijn, Peter, Vastbinder, Mijntje B., van Rossum-Schornagel, Quirine C., Thijs-Visser, Martine F., van Alphen, Robbert J., Struik, Liesbeth E. M., Zuetenhorst, Hanneke J. M., Mathijssen, Ron H. J., Koolen, Stijn L. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975771/
https://www.ncbi.nlm.nih.gov/pubmed/34786650
http://dx.doi.org/10.1007/s40262-021-01077-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975771/
https://www.ncbi.nlm.nih.gov/pubmed/34786650
http://dx.doi.org/10.1007/s40262-021-01077-z

Ejemplares similares